Dr. Carole Spangler Vaughn has over 25 years of experience in the Biotechnology and MedTech industries. She is a highly accomplished professional, with a solid reputation for high integrity, critical thinking, engaging and clear communication, and business insight. She is a recognized leader in technology assessment, excelling in applying appropriate business strategy to technology. Currently, Dr. Spangler Vaughn is the founder/CEO of Eisana Corp, an early stage company developing medical devices to prevent devastating side effects from cancer treatment, starting with a device to prevent permanent nerve damage in hands and feet, caused by many common chemotherapy drugs.

Prior to that, she was a consultant for health-related emerging companies, specializing in fund raising, business strategy, and sales/marketing. She also served as business advisor to the Global Food Protection Institute’s Emerging Technology Accelerator, and has been an Adjunct Professor in the graduate Business School at Seattle Pacific University. She has held a variety of positions in the biopharma/MedTech industry, working for large and small entities, both in the laboratory and in business development, including Bristol-Myers Squibb, University of Washington (Technology Transfer), Dendreon Corporation, and Clario Medical Imaging. She was a Strategy Consultant/Interim CEO for Emtora Biosciences. Dr. Spangler Vaughn holds a Ph.D. in Biophysics from The Johns Hopkins University and an MBA from the University of Washington. She is currently based in Houston, Texas.